"Graft vs Tumor Effect" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Immunological rejection of tumor tissue/cells following bone marrow transplantation.
Concept/Terms
Graft vs Tumor Effect- Graft vs Tumor Effect
- Graft vs Neoplasm Effect
- Graft-vs-Tumor Response
- Graft vs Tumor Response
- Graft-vs-Tumor Responses
- Response, Graft-vs-Tumor
- Responses, Graft-vs-Tumor
- Graft-vs-Neoplasm Response
- Graft vs Neoplasm Response
- Graft-vs-Neoplasm Responses
- Response, Graft-vs-Neoplasm
- Responses, Graft-vs-Neoplasm
- Graft-vs-Neoplasm Effect
- Effect, Graft-vs-Neoplasm
- Effects, Graft-vs-Neoplasm
- Graft-vs-Neoplasm Effects
- Graft-vs-Tumor Effect
- Effect, Graft-vs-Tumor
- Effects, Graft-vs-Tumor
- Graft-vs-Tumor Effects
Below are MeSH descriptors whose meaning is more general than "Graft vs Tumor Effect".
Below are MeSH descriptors whose meaning is more specific than "Graft vs Tumor Effect".
This graph shows the total number of publications written about "Graft vs Tumor Effect" by people in Harvard Catalyst Profiles by year, and whether "Graft vs Tumor Effect" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 2 | 2 | 4 |
| 2000 | 2 | 1 | 3 |
| 2001 | 0 | 2 | 2 |
| 2002 | 1 | 1 | 2 |
| 2003 | 4 | 1 | 5 |
| 2005 | 3 | 0 | 3 |
| 2006 | 1 | 2 | 3 |
| 2007 | 1 | 0 | 1 |
| 2008 | 2 | 1 | 3 |
| 2010 | 2 | 0 | 2 |
| 2011 | 1 | 1 | 2 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 2 | 0 | 2 |
| 2018 | 0 | 1 | 1 |
| 2021 | 0 | 2 | 2 |
Below are the most recent publications written about "Graft vs Tumor Effect" by people in Profiles.
-
Increased efficacy of dual proinflammatory cytokine blockade on acute GVHD while maintaining GVT effects. Blood. 2021 12 16; 138(24):2583-2588.
-
Recent Metabolic Advances for Preventing and Treating Acute and Chronic Graft Versus Host Disease. Front Immunol. 2021; 12:757836.
-
Autologous graft versus myeloma: it's not a myth. J Clin Invest. 2019 01 02; 129(1):48-50.
-
Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity. Nat Med. 2017 Feb; 23(2):242-249.
-
Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review. Immunotherapy. 2017 01; 9(2):123-130.
-
A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation. Haematologica. 2016 10; 101(10):1251-1259.
-
NKG2D expression by CD8+ T cells contributes to GVHD and GVT effects in a murine model of allogeneic HSCT. Blood. 2015 Jun 04; 125(23):3655-63.
-
Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015 Jun; 21(6):971-83.
-
A small-molecule c-Rel inhibitor reduces alloactivation of T cells without compromising antitumor activity. Cancer Discov. 2014 May; 4(5):578-91.
-
PLZF confers effector functions to donor T cells that preserve graft-versus-tumor effects while attenuating GVHD. Cancer Res. 2013 Aug 01; 73(15):4687-96.